CDC Measles Outbreak Response: Critical Epi-Aid Boost
CDC measles outbreak response: what Epi-Aid brings to Pennsylvania as cases hit 1,222, and why counting the true burden of an outbreak is hard.
Read More
Mosquito-Borne Diseases Europe: Alarming West Nile Record
Mosquito-borne diseases Europe: record West Nile season, 1,715 EU cases, first Belgian infections. How surveillance and mosquito control work.
Labcorp Bets on Lab Consolidation With OPKO Health Deal
Labcorp OPKO Health deal: $722M cash plus up to $150M for select BioReference assets. The economics, the logic and what could still change.
EU Panel Backs Revolution Medicines’ Rasonque for Pancreatic Cancer
Revolution Medicines Rasonque gets a CHMP positive opinion for pretreated metastatic pancreatic cancer. FDA approved it in August. What comes next in the EU.
AstraZeneca Pays $40 Million Upfront in AI Pact With insitro
AstraZeneca biotechnology partnership: $40M upfront, up to ~$1.46B in milestones with insitro for MASH and heart disease. See what is guaranteed.
Indian Pharma Companies Overseas: Zydus Eyes Sri Lanka Plant
Indian pharma companies overseas: Zydus plans a $20M-plus Sri Lanka plant with a local partner, operations from 2028. What it shows and what it does not.
New Celiac Disease Drugs Get a Bold ANB033 Result
New celiac disease drugs: First Tracks says ANB033 protected the gut in a 32-patient trial. See the 2027 roadmap, the risks and what is unknown.
Gilead Cancer Drug Pipeline Gets Bold Bet With Vir
The Gilead cancer drug pipeline adds three early Vir T-cell engagers. $90M upfront, up to about $1.88B in total. How the deal works and what is unknown.
mRNA Cancer Immunotherapy Setback: BNT113 Misses Endpoint
An mRNA cancer immunotherapy, BioNTech’s BNT113, missed its PFS goal in head and neck cancer. Overall survival is still being assessed. What it means.